BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

520 related articles for article (PubMed ID: 33410581)

  • 1. Inflammatory microenvironment of fibrotic liver promotes hepatocellular carcinoma growth, metastasis and sorafenib resistance through STAT3 activation.
    Jiang Y; Chen P; Hu K; Dai G; Li J; Zheng D; Yuan H; He L; Xie P; Tu M; Peng S; Qu C; Lin W; Chung RT; Hong J
    J Cell Mol Med; 2021 Feb; 25(3):1568-1582. PubMed ID: 33410581
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Dovitinib induces apoptosis and overcomes sorafenib resistance in hepatocellular carcinoma through SHP-1-mediated inhibition of STAT3.
    Tai WT; Cheng AL; Shiau CW; Liu CY; Ko CH; Lin MW; Chen PJ; Chen KF
    Mol Cancer Ther; 2012 Feb; 11(2):452-63. PubMed ID: 22180308
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Sorafenib inhibits growth and metastasis of hepatocellular carcinoma by blocking STAT3.
    Gu FM; Li QL; Gao Q; Jiang JH; Huang XY; Pan JF; Fan J; Zhou J
    World J Gastroenterol; 2011 Sep; 17(34):3922-32. PubMed ID: 22025881
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Sorafenib and its derivative SC-49 sensitize hepatocellular carcinoma cells to CS-1008, a humanized anti-TNFRSF10B (DR5) antibody.
    Chen KF; Chen HL; Shiau CW; Liu CY; Chu PY; Tai WT; Ichikawa K; Chen PJ; Cheng AL
    Br J Pharmacol; 2013 Feb; 168(3):658-72. PubMed ID: 22978563
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Emodin inhibits growth and induces apoptosis in an orthotopic hepatocellular carcinoma model by blocking activation of STAT3.
    Subramaniam A; Shanmugam MK; Ong TH; Li F; Perumal E; Chen L; Vali S; Abbasi T; Kapoor S; Ahn KS; Kumar AP; Hui KM; Sethi G
    Br J Pharmacol; 2013 Oct; 170(4):807-21. PubMed ID: 23848338
    [TBL] [Abstract][Full Text] [Related]  

  • 6. SC-2001 overcomes STAT3-mediated sorafenib resistance through RFX-1/SHP-1 activation in hepatocellular carcinoma.
    Su JC; Tseng PH; Wu SH; Hsu CY; Tai WT; Li YS; Chen IT; Liu CY; Chen KF; Shiau CW
    Neoplasia; 2014 Jul; 16(7):595-605. PubMed ID: 25047655
    [TBL] [Abstract][Full Text] [Related]  

  • 7. IL-22 signaling promotes sorafenib resistance in hepatocellular carcinoma via STAT3/CD155 signaling axis.
    Chen J; Sun S; Li H; Cai X; Wan C
    Front Immunol; 2024; 15():1373321. PubMed ID: 38596684
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A sorafenib derivative and novel SHP-1 agonist, SC-59, acts synergistically with radiotherapy in hepatocellular carcinoma cells through inhibition of STAT3.
    Huang CY; Tai WT; Hsieh CY; Hsu WM; Lai YJ; Chen LJ; Shiau CW; Chen KF
    Cancer Lett; 2014 Jul; 349(2):136-43. PubMed ID: 24735751
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Hypoxia-mediated sorafenib resistance can be overcome by EF24 through Von Hippel-Lindau tumor suppressor-dependent HIF-1α inhibition in hepatocellular carcinoma.
    Liang Y; Zheng T; Song R; Wang J; Yin D; Wang L; Liu H; Tian L; Fang X; Meng X; Jiang H; Liu J; Liu L
    Hepatology; 2013 May; 57(5):1847-57. PubMed ID: 23299930
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Differential effects of sorafenib on liver versus tumor fibrosis mediated by stromal-derived factor 1 alpha/C-X-C receptor type 4 axis and myeloid differentiation antigen-positive myeloid cell infiltration in mice.
    Chen Y; Huang Y; Reiberger T; Duyverman AM; Huang P; Samuel R; Hiddingh L; Roberge S; Koppel C; Lauwers GY; Zhu AX; Jain RK; Duda DG
    Hepatology; 2014 Apr; 59(4):1435-47. PubMed ID: 24242874
    [TBL] [Abstract][Full Text] [Related]  

  • 11. EPHB2 Activates β-Catenin to Enhance Cancer Stem Cell Properties and Drive Sorafenib Resistance in Hepatocellular Carcinoma.
    Leung HW; Leung CON; Lau EY; Chung KPS; Mok EH; Lei MML; Leung RWH; Tong M; Keng VW; Ma C; Zhao Q; Ng IOL; Ma S; Lee TK
    Cancer Res; 2021 Jun; 81(12):3229-3240. PubMed ID: 33903122
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Tumour initiating cells and IGF/FGF signalling contribute to sorafenib resistance in hepatocellular carcinoma.
    Tovar V; Cornella H; Moeini A; Vidal S; Hoshida Y; Sia D; Peix J; Cabellos L; Alsinet C; Torrecilla S; Martinez-Quetglas I; Lozano JJ; Desbois-Mouthon C; Solé M; Domingo-Domenech J; Villanueva A; Llovet JM
    Gut; 2017 Mar; 66(3):530-540. PubMed ID: 26658144
    [TBL] [Abstract][Full Text] [Related]  

  • 13. STAT3-mediated attenuation of CCl4-induced mouse liver fibrosis by the protein kinase inhibitor sorafenib.
    Deng YR; Ma HD; Tsuneyama K; Yang W; Wang YH; Lu FT; Liu CH; Liu P; He XS; Diehl AM; Gershwin ME; Lian ZX
    J Autoimmun; 2013 Oct; 46():25-34. PubMed ID: 23948302
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Induction of IL-6Rα by ATF3 enhances IL-6 mediated sorafenib and regorafenib resistance in hepatocellular carcinoma.
    Dai Z; Wang X; Peng R; Zhang B; Han Q; Lin J; Wang J; Lin J; Jiang M; Liu H; Lee TH; Lu KP; Zheng M
    Cancer Lett; 2022 Jan; 524():161-171. PubMed ID: 34687791
    [TBL] [Abstract][Full Text] [Related]  

  • 15. 17β-estradiol exerts anticancer effects in anoikis-resistant hepatocellular carcinoma cell lines by targeting IL-6/STAT3 signaling.
    Lee S; Lee M; Kim JB; Jo A; Cho EJ; Yu SJ; Lee JH; Yoon JH; Kim YJ
    Biochem Biophys Res Commun; 2016 May; 473(4):1247-1254. PubMed ID: 27091428
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Hepatocellular carcinoma cells and their fibrotic microenvironment modulate bone marrow-derived mesenchymal stromal cell migration in vitro and in vivo.
    Garcia MG; Bayo J; Bolontrade MF; Sganga L; Malvicini M; Alaniz L; Aquino JB; Fiore E; Rizzo MM; Rodriguez A; Lorenti A; Andriani O; Podhajcer O; Mazzolini G
    Mol Pharm; 2011 Oct; 8(5):1538-48. PubMed ID: 21770423
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Exosomes derived from HCC cells induce sorafenib resistance in hepatocellular carcinoma both in vivo and in vitro.
    Qu Z; Wu J; Wu J; Luo D; Jiang C; Ding Y
    J Exp Clin Cancer Res; 2016 Sep; 35(1):159. PubMed ID: 27716356
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Tumor-Associated Neutrophils Recruit Macrophages and T-Regulatory Cells to Promote Progression of Hepatocellular Carcinoma and Resistance to Sorafenib.
    Zhou SL; Zhou ZJ; Hu ZQ; Huang XW; Wang Z; Chen EB; Fan J; Cao Y; Dai Z; Zhou J
    Gastroenterology; 2016 Jun; 150(7):1646-1658.e17. PubMed ID: 26924089
    [TBL] [Abstract][Full Text] [Related]  

  • 19. C1orf61 promotes hepatocellular carcinoma metastasis and increases the therapeutic response to sorafenib.
    Yu Y; Wang Z; Huang Z; Tang X; Huang X; Li W
    Biochim Biophys Acta Mol Cell Res; 2021 Jul; 1868(8):119048. PubMed ID: 33915231
    [TBL] [Abstract][Full Text] [Related]  

  • 20. STAT3 mediates regorafenib-induced apoptosis in hepatocellular carcinoma.
    Tai WT; Chu PY; Shiau CW; Chen YL; Li YS; Hung MH; Chen LJ; Chen PL; Su JC; Lin PY; Yu HC; Chen KF
    Clin Cancer Res; 2014 Nov; 20(22):5768-76. PubMed ID: 25248379
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 26.